 
 
EXPLANATION:  CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW . 
        [Brackets ] indicate matter deleted from existing law.             *hb0158*      
HOUSE BILL 158  
J1   6lr1438  
  (PRE –FILED)    
By: Delegate Woods  
Requested: October 29, 2025  
Introduced and read first time: January 14, 2026  
Assigned to: Health  
 
A BILL ENTITLED  
 
AN ACT concerning  1 
 
Maryland Medical Assistance Program – Maternal Health Monitoring Pilot 2 
Program  3 
 
FOR the purpose of establishing the Maternal Health Monitoring Pilot Program in the 4 
Maryland Department of Health to support pregnant and postpartum Maryland 5 
Medical Assistance Program recipients who have higher risks of pregnancy 6 
complications because of maternal hypertension or maternal diabetes; and generally 7 
relating to the Maternal Health Monitoring Pilot Program.  8 
 
BY repealing a nd reenacting, without amendments,  9 
 Article – Health – General  10 
Section 15 –101(a) and (h)  11 
 Annotated Code of Maryland  12 
 (2023 Replacement Volume and 202 5 Supplement)  13 
 
BY adding to  14 
 Article – Health – General  15 
Section 15 –1301 and 15–1302 to be under the new subtitle “Subtitle 1 3. Maternal 16 
Health Monitoring Pilot Program”  17 
 Annotated Code of Maryland  18 
 (2023 Replacement Volume and 202 5 Supplement)  19 
 
 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 20 
That the Laws of Maryland read as follows:  21 
 
Article – Health – General  22 
 
15–101. 23 
 
 (a) In this title the following words have the meanings indicated.  24 
2 HOUSE BILL 158  
 
  
 (h) “Program” means the Maryland Medical Assistance Program.  1 
 
SUBTITLE 13. MATERNAL HEALTH MONITORING PILOT PROGRAM . 2 
 
15–1301. 3 
 
 (A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE  THE MEANINGS 4 
INDICATED . 5 
 
 (B) “ESCALATION PATHWAY ” MEANS AN AGREEMENT B ETWEEN A 6 
PARTICIPATING MANAGED CARE ORGANIZATION AN D A TECHNOLOGY VEND OR ON 7 
THE PROCEDURE TO BE USED WHEN AN ELIGIBLE PAR TICIPANT ’S HEALTH DATA  8 
WARRANT S FURTHER REVIEW AND I NVESTIGATION .  9 
 
 (C) “HEALTH CARE PROVIDER ” MEANS AN OBSTETRICIA N OR  A  10 
MATERNAL –FETAL MEDICINE PHYSI CIAN WHO IS :  11 
 
  (1) LICENSED IN THE STATE ; AND 12 
 
  (2) CARING FOR A PARTICIP ANT. 13 
 
 (D) “MATERNAL DIABETES ” MEANS DIABETES THAT :  14 
 
  (1) DEVELOPED PRIOR TO PR EGNANCY AND CONTINUE S DURING 15 
PREGNANCY ; OR  16 
 
  (2) DEVELOPS DURING PREGN ANCY .  17 
 
 (E) “MATERNAL HYPERTENSION ” MEANS HYPERTENSION T HAT: 18 
 
  (1) DEVELOPED PRIOR TO PR EGNANCY AND CONTINUE S DURING 19 
PREGNANCY ; OR 20 
 
  (2) DEVELOPS DURING PREGN ANCY .  21 
 
 (F) “PARTICIPANT ” MEANS AN INDIVIDUAL WHO MEETS THE 22 
REQUIREMENTS OF § 15–1302 OF THIS SUBTITLE AND  IS PARTICIPATING IN THE 23 
PILOT PROGRAM . 24 
 
 (G) “PARTICIPATING MANAGED  CARE ORGANIZATION ” MEANS A MANAGED 25 
CARE ORGANIZATION SE LECTED BY THE DEPARTMENT TO ADMINIS TER THE PILOT 26 
PROGRAM .  27 
 
 HOUSE BILL 158  3 
 
  (H) “PILOT PROGRAM ” MEANS THE MATERNAL HEALTH MONITORING 1 
PILOT PROGRAM .  2 
 
 (I) “REMOTE PATIENT MONITO RING” MEANS THE USE OF TEC HNOLOGY 3 
THAT : 4 
 
  (1) COLLECTS HEALTH DATA FROM AN ELIGIBL E PARTICIPANT AND 5 
ELECTRONICALLY TRANS MITS THE DATA SECURE LY THROUGH CELLULAR 6 
NETWORKS ; 7 
 
  (2) IS AUTHORIZED BY THE FEDERAL FOOD AND DRUG 8 
ADMINISTRATION ; AND   9 
 
  (3) MONITORS HEALTH DATA , INCLUDING : 10 
 
   (I) BLOOD PRESSURE ; 11 
 
   (II) WEIGHT; 12 
 
   (III) BLOOD GLUCOSE LEVELS ; AND  13 
 
   (IV) ANY OTHER PHYSIOLOGIC AL HEALTH DATA DETER MINED 14 
NECESSARY BY THE PAR TICIPANT ’S HEALTH CARE PROVID ER. 15 
 
 (J) “TECHNOLOGY VENDOR ” MEANS THE TECHNOLOGY  COMPANY 16 
SELECTED AND CONTRAC TED WITH BY A PARTICIPATING MAN AGED CARE 17 
ORGANIZATION .  18 
 
15–1302. 19 
 
 (A) THERE IS A MATERNAL HEALTH MONITORING PILOT PROGRAM IN THE 20 
DEPARTMENT . 21 
 
 (B) THE PURPOSE OF THE PILOT PROGRAM IS TO SUPPORT  PREGNANT AND 22 
POSTPARTUM PROGRAM RECIPIENTS WH O HAVE A HIGHER RISK  OF PREGNANCY 23 
COMPLICATION S BECAUSE OF MATERNA L HYPERTENSION OR MA TERNAL DIABETES .  24 
 
 (C) A PROGRAM RECIPIENT IS ELIGIBLE FOR THE PILOT PROGRAM IF THE 25 
PROGRAM RECIPIENT : 26 
 
  (1) IS PREGNANT ; 27 
 
4 HOUSE BILL 158  
 
   (2) IS A N ENROLLEE IN A PARTICIPATING MANAGE D CARE 1 
ORGANIZATION ; AND 2 
 
  (3) HAS BEEN D IAGNOSED WITH MATERN AL HYPERTENSION OR 3 
MATERNAL DIABETES .  4 
 
 (D) (1) THE DEPARTMENT SHALL :  5 
 
   (I) SELECT A T LEAST ONE  MANAGED CARE ORGANIZ ATION TO 6 
ADMINISTER THE PILOT PROGRAM IN A MANNER D ETERMINED BY THE 7 
DEPARTMENT ; AND 8 
 
   (II) SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION , PAY A 9 
$2,000  FEE PER PARTICIPANT TO A PARTICIPATING MANAGE D CARE ORGANIZATION 10 
TO ADMINISTER THE PILOT PROGRAM .  11 
 
  (2) THE TOTAL AMOUNT AWARDED BY THE PROGRAM TO 12 
PARTICIPATING MANAGE D CARE ORGANIZATION S UNDER PARAGRAPH (1)(II) OF 13 
THIS  SUBSECTION MAY NOT E XCEED $600,000.  14 
 
 (E) A PARTICIPATING MANAGE D CARE ORGANIZATION SHALL :  15 
 
  (1) CONTRACT WITH A TECHNOLOGY VENDOR TO  OFFER REMOTE 16 
PATIENT MONITORING S ERVICES TO PARTICIPA NTS; 17 
 
  (2) REIMBURSE THE TECHNOL OGY VENDOR FOR THE C OST OF 18 
PROVID ING REMOTE PATIENT M ONITORING SERVICES A ND DEVICES ; AND  19 
 
  (3) ENSURE PARTICIPANTS H AVE ACCESS TO REMOTE  MONITORING 20 
SERVICES UNDER THE PILOT PROGRAM .  21 
 
 (F) THE TECHNOLOGY VENDOR  SHALL :  22 
 
  (1) PROVIDE PREPROGRAMMED  TECHNOLOGY SPECIFIC TO EACH 23 
PARTICIPANT ; AND 24 
 
  (2) ENSURE THAT : 25 
 
   (I) REMOTE PATIENT MONITO RING OCCURS DURING T HE 26 
PARTICIPANT ’S SECOND AND THIRD T RIMESTERS AND FOR UP  TO 3 MONTHS 27 
POSTPARTUM ; 28 
 
 HOUSE BILL 158  5 
 
    (II) REMOTE PATIENT MONITO RING DEVICES ARE DEL IVERED 1 
TO EACH PARTICIPANT ; AND 2 
 
   (III) EACH PARTICIPANT IS T RAINED ON HOW TO USE  THE 3 
REMOTE PATIENT MONIT ORING DEVICE .  4 
 
 (G) (1) THE TECHNOLOGY VENDOR  SHALL EMPLOY A CLINICAL TEAM 5 
THAT INCLUDES : 6 
 
   (I) A NURSE LICENSED IN TH E STATE ; 7 
 
   (II) A DIETITIAN –NUTRITIONIST LICENSE D IN THE STATE ; AND 8 
 
   (III) A CERTIFIED DIABETES C ARE AND EDUCATION SP ECIALIST .  9 
 
  (2) THE CLINICAL TEAM EMPLOYED UNDER PARAGRAPH (1) OF THIS 10 
SUBSECTION SHALL SUP PORT EACH PARTICIPAN T BY: 11 
 
   (I) MONITORING AND REVIEW ING THE PARTICIPANT ’S HEALTH 12 
DATA ; 13 
 
   (II) ESTABLISHIN G, IN COLLABORATION WIT H A 14 
PARTICIPATING MANAGED CARE ORGANIZ ATION , AN ESCALATION  PATHWAY  TO BE 15 
COMPLIED WITH IF THE  PARTICIPANT ’S REMOTE PATIENT MON ITORING READINGS 16 
AND SYMPTOMS REQUIRE  IMMEDIATE ATTENTION FROM THE PARTICIPANT ’S 17 
HEALTH CARE PROVIDER ; AND  18 
 
   (III) PROVIDING HEALTH COAC HING TO EACH PARTICI PANT 19 
REGARDING :  20 
 
    1. CONDITION MANAGEMENT ; 21 
 
    2. HEALTH BEHAVIOR MODIF ICATION ; AND 22 
 
    3. NUTRITION .  23 
 
 (H) THE TECHNOLOGY VENDOR  SHALL ASSIGN A PROGR AM MANAGER TO : 24 
 
  (1) SUPPORT IMPLEMENTATIO N OF  THE PILOT PROGRAM ; AND 25 
 
  (2) COORDINATE EFFORTS BE TWEEN THE DEPARTMENT AND THE 26 
PARTICIPATING MANAGE D CARE ORGANIZATION . 27 
 
6 HOUSE BILL 158  
 
  (I) THE DEPARTMENT SHALL ENSU RE THAT PARTICIPATIO N IN THE PILOT 1 
PROGRAM REPRESENTS TH E GEOGRAPHIC DIVERSI TY OF THE STATE AND INCLUDE S 2 
A STATISTICALLY RELE VANT NUMBER OF PARTI CIPANTS .  3 
 
 (J) FOR FISCAL YEAR 2028, THE GOVERNOR SHALL INCLUD E IN THE 4 
ANNUAL BUDGET BILL A N APPROPRIATION OF $600,000  TO THE PROGRAM . 5 
 
 (K) THE PILOT PROGRAM SHALL OPERATE  DURING FISCAL YEARS 2027 6 
AND 2028. 7 
 
 (L) (1) ON OR BEFORE OCTOBER 1, 2028,  THE DEPARTMENT , IN 8 
CONJUNCTION WITH THE  PARTICIPATING MANAGE D CARE ORGANIZATION S AND THE 9 
TECHNOLOGY VENDOR S, SHALL REPORT ITS FIN DINGS AND RECOMMENDA TIONS TO 10 
THE GOVERNOR AND , IN ACCORDANCE WITH § 2–1257  OF THE STATE GOVERNMENT 11 
ARTICLE , THE GENERAL ASSEMBLY . 12 
 
  (2) IN ACCORDANCE WITH PA RAGRAPH (3) OF THIS SUBSECTION , THE 13 
REPORT REQUIRED UNDE R PARAGRAPH (1) OF THIS SUBSECTION S HALL PROVIDE 14 
INFORMATION  ON THE IMPACT  OF THE PILOT PROGRAM  ON: 15 
 
   (I) MARYLAND MEDICA L ASSISTANCE PROGRAM COSTS ; 16 
 
   (II) MATERNAL OUTCOMES , INCLUDING : 17 
 
    1. THE RATE OF : 18 
 
    A. MATERNAL MORTALITY ; 19 
 
    B. SEVERE MATERNAL  MORBIDITY ; 20 
 
    C. CAESAREAN SECTION S; 21 
 
    D. INTENSIVE CARE UNIT (ICU)  ADMISSION S; AND 22 
 
    E. POSTPARTUM HOSPITAL R EADMISSIONS ;  23 
 
    2. THE MEAN LENGTH OF HO SPITAL STAY ; AND 24 
 
    3. PREECLAMPSIA ; AND 25 
 
   (III) FETAL AND NEONATAL OU TCOMES , INCLUDING : 26 
 
    1. THE RATE OF : 27 
 HOUSE BILL 158  7 
 
  
    A. FETAL MORTALITY ; 1 
 
    B. FETAL GROWTH RESTRICT ION; 2 
 
    C. NEONATAL MORTALITY ; AND 3 
 
    D. NEONATAL INTENSIVE CARE UNIT (NICU)  4 
ADMISSIONS ;  5 
 
    2. THE MEAN LENGTH OF ST AY IN THE NICU;  6 
 
    3. NEONATAL HYPOGLYCEMIA ; 7 
 
    4. PRETERM BIRTHS ; 8 
 
    5. GESTATIONAL AGE AT DE LIVERY ; AND 9 
 
    6. BIRTHWEIGHT .  10 
 
  (3) IN DETERMIN ING THE PILOT PROGRAM ’S IMPACT ON THE ITEMS  11 
LISTED IN  PARAGRAPH (2) OF THIS SUBSECTION , THE DEPARTMENT SHALL  12 
EXAMINE  AVAILABLE PARTICIPAN T DATA , INCLUDING :  13 
 
   (I) CLAIMS DATA; 14 
 
   (II) VITAL STATISTICS DATA;  15 
 
   (III) ELECTRONIC HEALTH RECORD S; AND 16 
 
   (IV) ELECTRONIC MEDICAL RECORD S.  17 
 
  (4) THE REPORT REQUIRED UNDER PARAG RAPH (1) OF THIS 18 
SUBSECTION SHALL INCLUDE RECOMM ENDATIONS REGARDING WHETHER THE 19 
PILOT PROGRAM SHOULD BE IMPLEMENTE D STATEWIDE .  20 
 
 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall  take effect July 21 
1, 202 6. It shall remain effective for a period of 3 years and, at the end of June 30, 202 9, 22 
this Act, with no further action required by the General Assembly, shall be abrogated and 23 
of no further force and effect.  24 
 